|
1
|
de Thé H, Chomienne C, Lanotte M, Degos L
and Dejean A: The t(15;17) translocation of acute promyelocytic
leukaemia fuses the retinoic acid receptor alpha gene to a novel
transcribed locus. Nature. 347:558–561. 1990.PubMed/NCBI
|
|
2
|
Goddard AD, Borrow J, Freemont PS and
Solomon E: Characterization of a zinc finger gene disrupted by the
t(15;17) in acute promyelocytic leukemia. Science. 254:1371–1374.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tong JH, Dong S, Geng JP, Huang W, Wang
ZY, Sun GL, Chen SJ, Chen Z, Larsen CJ and Berger R: Molecular
rearrangements of the MYL gene in acute promyelocytic leukemia
(APL, M3) define a breakpoint cluster region as well as some
molecular variants. Oncogene. 7:311–316. 1992.PubMed/NCBI
|
|
4
|
Burnett AK, Grimwade D, Solomon E,
Wheatley K and Goldstone AH: Presenting white blood cell count and
kinetics of molecular remission predict prognosis in acute
promyelocytic leukemia treated with all-trans retinoic acid:
result of the Randomized MRC Trial. Blood. 93:4131–4143.
1999.PubMed/NCBI
|
|
5
|
Melnick A and Licht JD: Deconstructing a
disease: RARalpha, its fusion partners, and their roles in the
pathogenesis of acute promyelocytic leukemia. Blood. 93:3167–3215.
1999.PubMed/NCBI
|
|
6
|
Cohen MH, Hirschfeld S, Flamm Honig S,
Ibrahim A, Johnson JR, O'Leary JJ, White RM, Williams GA and Pazdur
R: Drug approval summaries: arsenic trioxide, tamoxifen citrate,
anastrazole, paclitaxel, bexarotene. Oncologist. 6:4–11. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM,
Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW,
Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z and Wang ZY: Use
of arsenic trioxide (As2O3) in the treatment
of acute promyelocytic leukemia (APL): II. Clinical efficacy and
pharmacokinetics in relapsed patients. Blood. 89:3354–3360.
1997.PubMed/NCBI
|
|
8
|
Soignet SL, Maslak P, Wang ZG, Jhanwar S,
Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J,
Scheinberg DA, Pandolfi PP and Warrell RP Jr: Complete remission
after treatment of acute promyelocytic leukemia with arsenic
trioxide. N Engl J Med. 339:1341–1348. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dilda PJ and Hogg PJ: Arsenical-based
cancer drugs. Cancer Treat Rev. 33:542–564. 2007. View Article : Google Scholar
|
|
10
|
Litzow MR: Arsenic trioxide. Expert Opin
Pharmacother. 9:1773–1785. 2008. View Article : Google Scholar
|
|
11
|
Fujisawa S, Ohno R, Shigeno K, Sahara N,
Nakamura S, Naito K, Kobayashi M, Shinjo K, Takeshita A, Suzuki Y,
Hashimoto H, Kinoshita K, Shimoya M, Kaise T and Ohnishi K:
Pharmacokinetics of arsenic species in Japanese patients with
relapsed or refractory acute promyelocytic leukemia treated with
arsenic trioxide. Cancer Chemother Pharmacol. 59:485–493. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iriyama N, Yoshino Y, Yuan B, Horikoshi A,
Hirabayashi Y, Hatta Y, Toyoda H and Takeuchi J: Speciation of
arsenic trioxide metabolites in peripheral blood and bone marrow
from an acute promyelocytic leukemia patient. J Hematol Oncol.
5:1–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kiguchi T, Yoshino Y, Yuan B, Yoshizawa S,
Kitahara T, Akahane D, Gotoh M, Kaise T, Toyoda H and Ohyashiki K:
Speciation of arsenic trioxide penetrates into cerebrospinal fluid
in patients with acute promyelocytic leukemia. Leuk Res.
34:403–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshino Y, Yuan B, Miyashita SI, Iriyama
N, Horikoshi A, Shikino O, Toyoda H and Kaise T: Speciation of
arsenic trioxide metabolites in blood cells and plasma of a patient
with acute promyelocytic leukemia. Anal Bioanal Chem. 393:689–697.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan B, Yoshino Y, Kaise T and Toyoda H:
Application of arsenic trioxide therapy for patients with
leukaemia. Biological Chemistry of As, Sb and Bi. Sun HZ: John
Wiley and Sons, Ltd; New York: pp. 263–292. 2011
|
|
16
|
Bhattacharjee H, Carbrey J, Rosen BP and
Mukhopadhyay R: Drug uptake and pharmacological modulation of drug
sensitivity in leukemia by AQP9. Biochem Biophys Res Commun.
322:836–841. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee TC, Ho IC, Lu WJ and Huang JD:
Enhanced expression of multidrug resistance-associated protein 2
and reduced expression of aquaglyceroporin 3 in an
arsenic-resistant human cell line. J Biol Chem. 281:18401–18407.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leung J, Pang A, Yuen WH, Kwong YL and Tse
EW: Relationship of expression of aquaglyceroporin 9 with arsenic
uptake and sensitivity in leukemia cells. Blood. 109:740–746. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Z, Shen J, Carbrey JM, Mukhopadhyay R,
Agre P and Rosen BP: Arsenite transport by mammalian
aquaglyceroporins AQP7 and AQP9. Proc Natl Acad Sci USA.
99:6053–6058. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshino Y, Yuan B, Kaise T, Takeichi M,
Tanaka S, Hirano T, Kroetz DL and Toyoda H: Contribution of
aquaporin 9 and multidrug resistance-associated protein 2 to
differential sensitivity to arsenite between primary cultured
chorion and amnion cells prepared from human fetal membranes.
Toxicol Appl Pharmacol. 257:198–208. 2011. View Article : Google Scholar
|
|
21
|
Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu
YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB,
Zelent A, Waxman S, Wang ZY, Chen SJ and Chen Z: Long-term efficacy
and safety of all-trans retinoic acid/arsenic trioxide-based
therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl
Acad Sci USA. 106:3342–3347. 2009.PubMed/NCBI
|
|
22
|
Yuan B, Ohyama K, Bessho T and Toyoda H:
Contribution of inducible nitric oxide synthase and
cyclooxygenase-2 to apoptosis induction in smooth chorion
trophoblast cells of human fetal membrane tissues. Biochem Biophys
Res Commun. 341:822–827. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuan B, Ohyama K, Bessho T, Uchide N and
Toyoda H: Imbalance between ROS production and elimination results
in apoptosis induction in primary smooth chorion trophoblast cells
prepared from human fetal membrane tissues. Life Sci. 82:623–630.
2008. View Article : Google Scholar
|
|
24
|
Yuan B, Ohyama K, Takeichi M and Toyoda H:
Direct contribution of inducible nitric oxide synthase expression
to apoptosis induction in primary smooth chorion trophoblast cells
of human fetal membrane tissues. Int J Biochem Cell Biol.
41:1062–1069. 2009. View Article : Google Scholar
|
|
25
|
Wang ZY and Chen Z: Acute promyelocytic
leukemia: from highly fatal to highly curable. Blood.
111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J,
Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J,
Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S,
Wang ZY, de The H, Chen SJ and Chen Z: Use of arsenic trioxide
(As2O3) in the treatment of acute
promyelocytic leukemia (APL): I. As2O3 exerts
dose-dependent dual effects on APL cells. Blood. 89:3345–3353.
1997.PubMed/NCBI
|
|
27
|
Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen
SJ and Chen Z: Arsenic trioxide, a therapeutic agent for APL.
Oncogene. 20:7146–7153. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Di Bona E, Sartori R, Zambello R, Guercini
N, Madeo D and Rodeghiero F: Prognostic significance of CD56
antigen expression in acute myeloid leukemia. Haematologica.
87:250–256. 2002.
|
|
29
|
Ferrara F, Morabito F, Martino B, Specchia
G, Liso V, Nobile F, Boccuni P, Di Noto R, Pane F, Annunziata M,
Schiavone EM, De Simone M, Guglielmi C, Del Vecchio L and Lo Coco
F: CD56 expression is an indicator of poor clinical outcome in
patients with acute promyelocytic leukemia treated with
simultaneous all-trans-retinoic acid and chemotherapy. J
Clin Oncol. 18:1295–1300. 2000.PubMed/NCBI
|
|
30
|
Montesinos P, Rayon C, Vellenga E, Brunet
S, Gonzalez J, Gonzalez M, Holowiecka A, Esteve J, Bergua J,
Gonzalez JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G,
de la Serna J, Perez I, Perez-Encinas M, Krsnik I, Ribera JM,
Escoda L, Lowenberg B and Sanz MA: Clinical significance of CD56
expression in patients with acute promyelocytic leukemia treated
with all-trans retinoic acid and anthracycline-based regimens.
Blood. 117:1799–1805. 2011. View Article : Google Scholar
|
|
31
|
Schwarzinger I, Valent P, Koller U, Marosi
C, Schneider B, Haas O, Knapp W, Lechner K and Bettelheim P:
Prognostic significance of surface marker expression on blasts of
patients with de novo acute myeloblastic leukemia. J Clin Oncol.
8:423–430. 1990.PubMed/NCBI
|
|
32
|
Vahdat L, Maslak P, Miller WH Jr, Eardley
A, Heller G, Scheinberg DA and Warrell RP Jr: Early mortality and
the retinoic acid syndrome in acute promyelocytic leukemia: impact
of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and
CD13 expression in patients treated with all-trans retinoic acid.
Blood. 84:3843–3849. 1994.PubMed/NCBI
|
|
33
|
Andus T, Targan SR, Deem R and Toyoda H:
Measurement of tumor necrosis factor alpha mRNA in small numbers of
cells by quantitative polymerase chain reaction. Reg Immunol.
5:11–17. 1993.PubMed/NCBI
|
|
34
|
Ruan XZ, Varghese Z, Powis SH and Moorhead
JF: Human mesangial cells express inducible macrophage scavenger
receptor. Kidney Int. 56:440–451. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou
L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z and Chen
GQ: Arsenic trioxide-induced apoptosis and differentiation are
associated respectively with mitochondrial transmembrane potential
collapse and retinoic acid signaling pathways in acute
promyelocytic leukemia. Leukemia. 14:262–270. 2000. View Article : Google Scholar
|
|
36
|
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ,
Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang
P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY and Chen Z: In vitro
studies on cellular and molecular mechanisms of arsenic trioxide
(As2O3) in the treatment of acute
promyelocytic leukemia: As2O3 induces NB4
cell apoptosis with downregulation of Bcl-2 expression and
modulation of PML-RAR alpha/PML proteins. Blood. 88:1052–1061.
1996.PubMed/NCBI
|
|
37
|
Iriyama N, Yuan B, Hatta Y, Horikoshi A,
Yoshino Y, Toyoda H, Aizawa S and Takeuchi J: Granulocyte
colony-stimulating factor potentiates differentiation induction by
all-trans retinoic acid and arsenic trioxide and enhances
arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Oncol Rep. 28:1875–1882. 2012.PubMed/NCBI
|
